Kelly J D, Williamson K E, Weir H P, McManus D T, Hamilton P W, Keane P F, Johnston S R
Department of Urology, Belfast City Hospital, Belfast, N. Ireland, UK.
BJU Int. 2000 May;85(7):911-7. doi: 10.1046/j.1464-410x.2000.00667.x.
To examine mitomycin-C (MMC)-induced apoptosis in an ex vivo model of superficial TCC, and relate it to the in vivo response to chemotherapy. Materials and methods Dose- and time-response curves were constructed to determine the optimal conditions for the induction of apoptosis by MMC in an ex vivo model of superficial bladder cancer. Subsequently, 41 individual tumours were exposed to MMC in the model and the effects assessed by measuring of apoptosis before and after chemotherapy. The relationships between tumour grade and stage and the intrinsic and induced apoptotic counts were determined. In tandem, in a clinical study, the relationship between in vivo response of a marker tumour to MMC and the ex vivo induction of apoptosis was determined.
In the ex vivo model, apoptosis was induced at a MMC concentration of 0.5 mg/mL after an incubation time of 8 h. In 41 tumours the intrinsic apoptotic index (AI) was higher with increased grade and stage of tumour (P = 0.048). There was no correlation between the intrinsic AI and the AI after treatment with MMC (induced AI). In 21 tumours (51%) the induced AI did not increase above a predetermined response threshold and these tumours were considered resistant to MMC. Resistance to MMC was related to tumour grade (P = 0.037) with a trend for G3 pT1 tumours to be resistant to the therapy. There was a significant association between ex vivo sensitivity and in vivo marker tumour response (P = 0.02).
Apoptosis is differentially induced in an ex vivo incubation model of superficial TCC by MMC and evidence suggests that this response matches that seen in vivo. The measurement of apoptosis before therapy does not predict the apoptotic response of a tumour to chemotherapy. The ability to undergo apoptosis correlates with clinical outcome.
在浅表性移行细胞癌的体外模型中研究丝裂霉素-C(MMC)诱导的细胞凋亡,并将其与体内化疗反应相关联。材料与方法构建剂量-反应曲线和时间-反应曲线,以确定在浅表性膀胱癌体外模型中MMC诱导细胞凋亡的最佳条件。随后,在该模型中对41个个体肿瘤进行MMC处理,并通过测量化疗前后的细胞凋亡情况评估其效果。确定肿瘤分级和分期与固有及诱导凋亡计数之间的关系。同时,在一项临床研究中,确定标记肿瘤对MMC的体内反应与体外诱导细胞凋亡之间的关系。
在体外模型中,孵育8小时后,0.5mg/mL的MMC浓度可诱导细胞凋亡。在41个肿瘤中,固有凋亡指数(AI)随肿瘤分级和分期的增加而升高(P = 0.048)。固有AI与MMC处理后的AI(诱导AI)之间无相关性。在21个肿瘤(51%)中,诱导AI未升高至预定反应阈值以上,这些肿瘤被认为对MMC耐药。对MMC的耐药性与肿瘤分级相关(P = 0.037),G3 pT1肿瘤有对该治疗耐药的趋势。体外敏感性与体内标记肿瘤反应之间存在显著关联(P = 0.02)。
在浅表性移行细胞癌的体外孵育模型中,MMC可不同程度地诱导细胞凋亡,证据表明这种反应与体内观察到的反应相符。治疗前细胞凋亡的测量不能预测肿瘤对化疗的凋亡反应。发生细胞凋亡的能力与临床结果相关。